# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $...
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell...
Marker Therapeutics (NASDAQ:MRKR) reported quarterly losses of $(0.27) per share. This is a 52.63 percent increase over losses ...
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and anno...
At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The Company believes that its existing cash and ca...
Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its ...